Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors

Human immunodeficiency virus type 1 (HIV-1) variants that have developed protease (PR) inhibitor resistance most often display cross-resistance to several molecules within this class of antiretroviral agents. The clinical benefit of the switch to a second PR inhibitor in the presence of such resista...

Полное описание

Библиографические подробности

Опубликовано в::	J Virol
Главные авторы:	Dulioust, Anne, Paulous, Sylvie, Guillemot, Laurent, Delavalle, Anne-Marie, Boué, François, Clavel, François
Формат:	Artigo
Язык:	Inglês
Опубликовано:	American Society for Microbiology (ASM) 1999
Предметы:	Vaccines and Antiviral Agents
Online-ссылка:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC103902/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9847401/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.73.1.850-854.1999
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!